13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-10-14 Event 2026-10-13 SEC 0001213900-26-109425 →

Keller Eric L. → Retension Pharmaceuticals, Inc. RTSN

Stake: 7.07% Shares: 598,598 CUSIP: 76135H100 Class: Common Stock, par value $0.0001 per share

Item 4 — Purpose of Transaction

The Reporting Person acquired beneficial ownership of the securities reported herein in as Chief Executive Officer, a member of the board of directors (the "Board") and a co-founder of the Issuer, for investment purposes, and as compensation from the Issuer. In his capacity as Chief Executive Officer and a member of the Board of the Issuer, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person expects to review from time to time his investment in the Issuer and may, depending on the market and other conditions and applicable legal requirements, (i) purchase or acquire additional shares of Common Stock in the open market, in privately negotiated transactions, or otherwise; (ii) sell or dispose of all or a portion of the shares of Common Stock now beneficially owned or hereafter acquired by him; and (iii) engage in communications with, without limitation, other officers and employees of the Issuer, other shareholders of the Issuer, members of the Board, or other relevant parties regarding the Issuer, including but not limited to its business, operations, governance, and control. Other than as described herein, the Reporting Person does not have any plans or proposals relating to or that would result in any of the events or matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, subject to applicable legal requirements, the Reporting Person may, at any time and from time to time, participate in discussions concerning, or formulate or review plans or proposals that may result in, one or more of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Cross-References

Insider Activity (last 365d)
2 transactions
2 buys · 0 sales · 0 awards/exercises
Issuer Cluster
1 13D/G filings on this issuer
0 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest
—
Not in latest FINRA snapshot

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-10-08 BERENDT MICHAEL J director Award 5,636 $12.00 $68K
2026-10-08 Olds Donald director Award 5,636 $12.00 $68K

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →